- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Natco Pharma Limited — Important, 05-01-2026: Updates
05-01-2026 | 05:11 pm
05-01-2026 | 05:11 pm
NATCO Pharma posted robust financials: revenue grew 16% to ₹4,784 Cr, PAT jumped 36% to ₹1,883 Cr, with 53.30% EBITDA. The company expanded global presence and R&D (₹373.3 Cr spend) in new therapies. NATCO earned a GreenCo Gold rating, upholding strong compliance with no product recalls.
No comments yet. Be the first to comment!